Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- AI Companion Tool Identifies Food Triggers Based on IBS Sensitivity Testing (CLP)
- British startup BoobyBiome raises €2.8 million for infant health with breast milk microbiome breakthrough (EU-Startups)
- Locum tenens: Reclaiming purpose, autonomy, and financial freedom in medicine (KevinMD)
- Getting Ahead of Gastrointestinal Cancer (Medscape)
- Can AI and Molecular Testing Outperform Colonoscopy? (The Pathologist)
- Precision Gastroenterology: Harnessing Personalized Medicine for Transformative Patient Care (ASGE)
- Transforming Colonoscopy: The Role of Mechanical Enhancements in Boosting Polyp Detection Rates (ReachMD)
- Health Insurance Premiums To Rise Well Above Inflation For Most Americans (Forbes)